Eye Care Benefits of Anti-Aging Compound Capsules in Healthy Adults

China Medical University Hospital25 enrolled

Overview

This study aims to evaluate the eye care benefits of anti-aging compound capsules in healthy adults. Participants will consume anti-aging compound capsules containing botanical extracts, omega-3 fatty acids, vitamins, minerals, and hyaluronic acid for four weeks. The primary outcome is the improvement of ocular discomfort and eye fatigue symptoms assessed using the Ocular Surface Disease Index (OSDI). Secondary outcomes include visual acuity, accommodative function, tear film stability, macular pigment optical density, intraocular pressure, and photostress recovery time. The study will investigate whether daily supplementation with anti-aging compound capsules can improve visual comfort and support ocular health.

Visual fatigue and ocular discomfort have become increasingly prevalent due to prolonged use of digital devices, environmental stressors, and age-related changes in visual function. Nutritional supplementation containing antioxidants, carotenoids, omega-3 fatty acids, vitamins, minerals, and other bioactive compounds may help maintain ocular health and visual performance. This prospective, single-arm, open-label clinical study aims to evaluate the eye care benefits of anti-aging compound capsules in healthy adults. Twenty-five participants will be enrolled and instructed to consume anti-aging compound capsules for four consecutive weeks. Each capsule contains 550 mg of a proprietary formulation consisting of grape skin extract, marigold flower extract, red algae extract, fish oil, black soybean seed coat extract, Streptococcus fermentation products containing sodium hyaluronate, black pepper extract, zinc glycinate, selenium yeast, vitamins A, B1, B2, B6, B12, niacin, vitamin E, soybean lecithin, and glycerol fatty acid esters. Participants will consume two capsules twice daily for a total daily intake of 2,200 mg. Ophthalmic assessments will be performed at baseline, Week 2, and Week 4. The primary outcome measure is the Ocular Surface Disease Index (OSDI) score. Secondary outcome measures include distance visual acuity, near visual acuity, accommodative response, accommodative facility, tear film break-up time, macular pigment optical density, intraocular pressure, and photostress recovery time. The study aims to determine whether supplementation with anti-aging compound capsules can improve eye fatigue symptoms and support ocular health in healthy adults.

Study Type

INTERVENTIONAL

Allocation

Interventions

Anti-Aging Compound CapsulesDIETARY_SUPPLEMENT

Participants will consume anti-aging compound capsules twice daily for 4 weeks. Each capsule contains 550 mg of a proprietary formulation consisting of grape skin extract, marigold flower extract, red algae extract, fish oil, black soybean seed coat extract, Streptococcus fermentation products containing sodium hyaluronate, black pepper extract, zinc glycinate, selenium yeast, vitamins A, B1, B2, B6, B12, niacin, vitamin E, soybean lecithin, and glycerol fatty acid esters. Total daily intake is 2,200 mg.

Eligibility

Sex: ALLMin age: 20 YearsMax age: 60 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Adults aged 20 to 60 years. Willing to participate in the study and able to provide written informed consent. Spherical equivalent refractive error less than 700 diopters of myopia (i.e., \< -7.00 D). Exclusion Criteria: * Regular consumption within the past 1 month of dietary supplements primarily indicated for eye health, or products containing active ocular health-related ingredients that may influence study outcomes (e.g., high-dose lutein ≥10 mg/day or zeaxanthin ≥2 mg/day). Use of general multivitamins or non-eye-specific supplements containing low-dose related ingredients (≤2 mg) may be allowed at the discretion of the investigators. History of ocular infection or ocular surgery within the past 3 months. Clinically diagnosed ocular diseases, including but not limited to glaucoma, cataract, age-related macular degeneration, or diabetic retinopathy, or a history of ocular procedures such as cataract surgery, retinal laser therapy, or refractive surgery (e.g., LASIK). Known or self-reported hypersensitivity or allergic reaction to any component of the investigational product, including but not limited to fish oil, soybean-derived products, gelatin (bovine source), yeast, or any other listed ingredients. Individuals with direct affiliation, supervisory, evaluative, or dependent relationships with the research team, including but not limited to: Students taught, supervised, or evaluated by members of the research team; Laboratory or research assistants, staff, or collaborators within the same research unit; Interns, part-time workers, or employees under the supervision of the research team.

Outcomes

Primary Outcomes

Change in Ocular Surface Disease Index (OSDI) Score

Changes in ocular discomfort and eye fatigue symptoms will be assessed using the Ocular Surface Disease Index (OSDI) questionnaire. The OSDI is a validated 12-item questionnaire used to evaluate symptoms related to ocular surface disease and visual function. Assessments will be performed at baseline, Week 2, and Week 4. A decrease in OSDI score indicates improvement in ocular symptoms.